At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
WGS GeneDx Holdings
Market Closed 02-20 16:00:00 EST
82.06
-8.62
-9.51%
盘后83.00
+0.94+1.15%
19:57 EST
High90.88Low81.60Vol876.18K
Open89.22D1 Closing90.68Amplitude10.23%
Mkt Cap2.37BTradable Cap1.64BTotal Shares28.90M
T/O74.11MT/O Rate4.39%Tradable Shares19.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: GeneDx Holdings revenue is expected to increase by 46.43%, and institutional views are mostly bullish
Earnings Agent  ·  02-16
Earning Preview: GeneDx Holdings revenue is expected to increase by 46.43%, and institutional views are mostly bullish
BRIEF-Time Names Genedx CEO Katherine Stueland To The 2026 Time100 Health List Of The World’S Most Influential Leaders In Health
Reuters  ·  02-11
BRIEF-Time Names Genedx CEO Katherine Stueland To The 2026 Time100 Health List Of The World’S Most Influential Leaders In Health
Time Names GeneDx CEO Katherine Stueland to the 2026 Time100 Health List of the World’s Most Influential Leaders in Health
THOMSON REUTERS  ·  02-11
Time Names GeneDx CEO Katherine Stueland to the 2026 Time100 Health List of the World’s Most Influential Leaders in Health
Wells Fargo Upgrades GeneDx Holdings to Overweight From Equalweight
MT Newswires Live  ·  02-09
Wells Fargo Upgrades GeneDx Holdings to Overweight From Equalweight
GeneDx Holdings Corp. : Wells Fargo Raises to Overweight From Equal Weight
THOMSON REUTERS  ·  02-09
GeneDx Holdings Corp. : Wells Fargo Raises to Overweight From Equal Weight
U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup
Reuters  ·  02-09
U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup
GeneDx COO Bryan Dechairo Reports Disposal of Common Shares
Reuters  ·  02-07
GeneDx COO Bryan Dechairo Reports Disposal of Common Shares
GeneDx Holdings Corp. to Release Fourth Quarter Financial Results
Reuters  ·  02-03
GeneDx Holdings Corp. to Release Fourth Quarter Financial Results
Analysts Are Bullish on Top Healthcare Stocks: Immutep Ltd (PRRUF), GeneDx Holdings (WGS)
TIPRANKS  ·  02-02
Analysts Are Bullish on Top Healthcare Stocks: Immutep Ltd (PRRUF), GeneDx Holdings (WGS)
Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx today
TIPRANKS  ·  01-31
Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx today
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
GlobeNewswire  ·  01-27
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives
Simply Wall St.  ·  01-16
GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives
Health Minister Responds to Reports of Two Super Flu Cases in Bali
Tempo  ·  01-15
Health Minister Responds to Reports of Two Super Flu Cases in Bali
Stock Track | GeneDx Holdings Plummets 5.07% Intraday Amid Mixed Analyst Opinions
Stock Track  ·  01-13
Stock Track | GeneDx Holdings Plummets 5.07% Intraday Amid Mixed Analyst Opinions
GeneDx Shares Down 2.5% After Announcing Preliminary Q4 Results, 2026 Outlook
THOMSON REUTERS  ·  01-12
GeneDx Shares Down 2.5% After Announcing Preliminary Q4 Results, 2026 Outlook
GeneDx Reports Preliminary Q4 Revenue; Issues 2026 Revenue Guidance
MT Newswires Live  ·  01-12
GeneDx Reports Preliminary Q4 Revenue; Issues 2026 Revenue Guidance
Genedx Holdings Corp. unveils presentation highlighting advances in rare disease diagnosis and genomics-driven healthcare
Reuters  ·  01-12
Genedx Holdings Corp. unveils presentation highlighting advances in rare disease diagnosis and genomics-driven healthcare
GeneDx reports preliminary Q4 revenue $121M, consensus $120.49M
TIPRANKS  ·  01-12
GeneDx reports preliminary Q4 revenue $121M, consensus $120.49M
GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth
Reuters  ·  01-12
GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
THOMSON REUTERS  ·  01-12
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

Introduction

Company Name.
GeneDx Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.
Issue price:
--